Breast Cancer Type 2 susceptibility protein (BRCA2) is a tumour suppressor gene. BRCA2 is involved in the repair of chromosomal damage, specifically in localising Rad51 to double strand breaks. BRCA2 and BRCA1 are frequently mutated in cases of hereditary breast and ovarian cancer.
| Inventor | Institute |
|---|---|
| Madalena Tarsounas | Cancer Research UK, London Research Institute: Clare Hall Laboratories |
| Cat. #: | 151571 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Cancer types: | Breast cancer;Gynaecologic cancer |
| Research Fields: | Cancer;Genetics |
| Application: | ChIP ; IP ; WB |
| Target: | BRCA2 |
| Reactivity: | Human ; Mouse |
| Clone: | MTA42 |
| Host: | Rabbit |
| Class: | Polyclonal |
| Alternate name: | BRCA 2, BRCA1/BRCA2 containing complex subunit 2, Brca2, BRCA2_HUMAN, BRCC 2, BRCC2, Breast and ovarian cancer susceptibility gene early onset, Breast cancer 2 early onset, Breast Cancer 2 tumor suppressor, Breast cancer susceptibility protein BRCA2, Breast cancer type 2 susceptibility protein, BROVCA2, FACD, FAD 1, FAD, FAD1, FANCB, FANCD 1 |
|---|---|
| Product description: | Breast Cancer Type 2 susceptibility protein (BRCA2) is a tumour suppressor gene. BRCA2 is involved in the repair of chromosomal damage, specifically in localising Rad51 to double strand breaks. BRCA2 and BRCA1 are frequently mutated in cases of hereditary breast and ovarian cancer. |
| Conjugation: | Unconjugated |
| Molecular weight: | 370 kDa |
| Immunogen: | Human BRCA2 sequence |
| Target background: | Breast Cancer Type 2 susceptibility protein (BRCA2) is a tumour suppressor gene. BRCA2 is involved in the repair of chromosomal damage, specifically in localising Rad51 to double strand breaks. BRCA2 and BRCA1 are frequently mutated in cases of hereditary breast and ovarian cancer. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1.47 mg/ml |
| Storage buffer: | PBS, 0.1% NaN3 |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Zhang et al. 2012. Clin Cancer Res. 18(21):5961-71. PMID: 22977194. FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51. Badie et al. 2010. Nat Struct Mol Biol. 17(12):1461-9. PMID: 21076401. BRCA2 acts as a RAD51 loader to facilitate telomere replication and capping. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151015 | Anti-CyclinA [E70.1] |
Key Info
Anti-CyclinA [E70.1]
|
View Tool | |||||||||||||||||||
| 151019 | Anti-Mos [S3.1] |
Key Info
Anti-Mos [S3.1]
|
View Tool | |||||||||||||||||||
| 151021 | Anti-CyclinB1 [V152] |
Key Info
Anti-CyclinB1 [V152]
|
View Tool | |||||||||||||||||||
| 151034 | Anti-HSVUL42 [13D11] |
Key Info
Anti-HSVUL42 [13D11]
|
View Tool | |||||||||||||||||||
| 151020 | Anti-CyclinB1 [V143.1] |
Key Info
Anti-CyclinB1 [V143.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.